Retrospective cohort study of age threshold for oxaliplatin benefit in stage II and III colorectal cancer
Prof. Sanghee Kang
A population-based, retrospective cohort study in South Korea investigated to age threshold for a survival benefit of adding oxaliplatin to fluoropyrimidine-based adjuvant chemotherapy among older patients with stage II or III colorectal cancer. In this cohort study of 8561 Korean patients, oxaliplatin was associated with improved overall survival among patients aged 70 years or younger with stage III disease but not among those older than 70 years or those with stage II disease. The authors conclude that use of adjuvant oxaliplatin in stage III patients older than 70 years and stage II patients warrants reconsideration.
